Corrigendum to "Characterization, bioactivity and pharmacokinetic study of a novel carbohydrate-peptide polymer: Glycol-split heparin-endostatin2 (GSHP-ES2)" [Carbohydrate Polymers 207 (2019) 79-90].

A new correction just dropped for one of the more interesting peptide-polymer studies in recent years. The team behind the original glycol-split heparin-endostatin2 (GSHP-ES2) work—Sun, Wang, Yang, and colleagues from Shandong University—has issued a corrigendum for their 2019 paper on this novel carbohydrate-peptide polymer. If you care about hybrid molecules or bioactive research peptides, this is one to watch.

GSHP-ES2 isn’t your garden-variety peptide. It’s a fusion of a split heparin backbone with endostatin2, engineered to tweak bioactivity and pharmacokinetics. The original paper detailed the synthesis, biological effects, and how the molecule moves through the body. That research got attention for showing how structural tweaks in carbohydrate-peptide polymers can change both function and stability—core questions for anyone designing next-gen research peptides.

Now, the corrigendum doesn’t overturn the main results. Instead, it clarifies details and corrects minor errors—standard stuff in fast-moving research fields. The key message holds: hybrid polymers like GSHP-ES2 keep opening new doors for peptide applications in bioengineering, pharma, and beyond.

Why it matters:

For anyone who wants the big picture on hybrid and advanced peptide work, the peptide research index is the place to start. You’ll find the latest on fusion peptides, polymers, and everything in between.

Research keeps moving, and so does the science behind peptide-based polymers. Keep an eye on these corrections—they’re part of how good research gets even better.